Danaher (DHR) is a publicly traded Healthcare sector company. As of July 5, 2026, DHR trades at $197.93 with a market cap of $140.09B and a P/E ratio of 38.14. DHR moved +2.17% today. Year to date, DHR is -14.19%; over the trailing twelve months it is -2.26%. Its 52-week range spans $160.93 to $258.23. Analyst consensus is strong buy with an average price target of $228.80. Rallies surfaces DHR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Danaher Foundation Pledges $1M for Ebola Response in DRC, Uganda: Danaher Foundation committed $1 million to support Ebola Bundibugyo outbreak response in the DRC and Uganda through Save the Children, International Rescue Committee and World Food Programme USA, funding infection prevention, hygiene and emergency food assistance. The grant underscores Danaher’s global health focus but delivers no revenue benefit.
| Metric | Value |
|---|---|
| Price | $197.93 |
| Market Cap | $140.09B |
| P/E Ratio | 38.14 |
| EPS | $5.19 |
| Dividend Yield | 0.40% |
| 52-Week High | $258.23 |
| 52-Week Low | $160.93 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $24.78B |
| Net Income | $3.69B |
| Gross Margin | 58.94% |
22 analysts cover DHR: 0 strong buy, 18 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $228.80.